Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biondvax Pharma ADR (NQ: BVXV )

1.860 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.860
Bid (Size) 1.880 (16)
Ask (Size) 1.990 (15)
Prev. Close 1.860
Today's Range 1.860 - 1.860
52wk Range 1.700 - 13.80
Shares Outstanding 461,285,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Provides Business Update, Reports FY2022 Financial Results
Via Investor Brand Network

Performance

YTD
-38.18%
-38.18%
1 Month
-0.53%
-0.53%
3 Month
-21.02%
-21.02%
6 Month
-80.52%
-80.52%
1 Year
-86.12%
-86.12%

More News

Read More
New Evidence Proves Link Between Glandular Fever Virus and MS
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Looking to Complement Core Focus with CDMO Offering
Via Investor Brand Network
Biden Signs Measure to End National COVID-19 Emergency
Via Investor Brand Network
Topics Government
Exposures COVID-19 Political
Eczema or Asthma Predisposes Individuals to Osteoarthritis
Via Investor Brand Network
African Researchers Collaborate to Gather Data on Infectious Illnesses
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q1 2023 Financial Results, Business Update
Via Investor Brand Network
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
Via ACCESSWIRE
Study Finds 10% of People in UK Have Autoimmune Disorders
Via Investor Brand Network
Researchers ID Antivirals That Can Fight New Infectious Illnesses
Via Investor Brand Network
Exposures COVID-19
Study Shows that Skin Conditions May Indicate Presence of Rheumatic Disease
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aims to Complement its NanoAb Core Focus with Comprehensive Contract Development 2and Manufacturing Organization Services
Via Investor Brand Network
Study Finds That Different Subtypes of Epilepsy Trigger Different Autoimmune Conditions
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Equity Research Report
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports FY 2022 Financial Statements, Corporate Update
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland
Via Investor Brand Network
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Innovative NanoAb Pipeline to Disrupt High-Value Market Opportunities
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
Via Investor Brand Network
Exposures COVID-19
Scientists Sound Alarm on Climate-Change-Induced Rise of Deadly infections
Via Investor Brand Network
Topics Climate Change
Exposures Climate
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants
Via Investor Brand Network
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.